ZIM LABORATORIES share price has zoomed 10% and is presently trading at Rs 118.0.
Meanwhile, the BSE HEALTHCARE index is at 44,256.3 (up 0.7%).
Among the top gainers in the BSE HEALTHCARE index today are Procter & Gamble Health (up 4.0%) and SYNGENE INTERNATIONAL (up 3.0%).
GLAND PHARMA (down 1.4%) and Abbott India (down 1.3%) are among the top losers today.
Over the last one year, ZIM LABORATORIES has moved down from Rs 122.9 to Rs 118.0, registering a loss of Rs 4.9 (down 4.0%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,089.2 to 44,256.3, registering a gain of 57.6% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 209.3%), SUVEN PHARMACEUTICALS (up 134.6%) and Glenmark Pharma (up 131.2%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 80,031.2 (up 0.7%).
The top gainers among the BSE Sensex today are HCl Tech. (up 3.6%) and TCS (up 3.5%). The most traded stocks in the BSE Sensex are ITC and Infosys.
In the meantime, NSE Nifty is at 24,381.8 (up 0.7%). TCS and HCl Tech. are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 64,958.7 to 80,031.2, registering a gain of 15,072.5 points (up 23.2%).
ZIM LABORATORIES net profit grew 297.3% YoY to Rs 9 million for the quarter ended June 2024, compared to a profit of Rs 2 million a year ago. Net sales rose 21.3% to Rs 818 million during the period as against Rs 674 million in April-June 2023.
For the year ended March 2024, ZIM LABORATORIES reported 29.4% decrease in net profit to Rs 172 million compared to net profit of Rs 244 million during FY23. Revenue of the company fell 7.8% to Rs 3,674 million during FY24.
The current Price to earnings ratio of ZIM LABORATORIES, based on rolling 12 month earnings, stands at 32.1.
Equitymaster requests your view! Post a comment on "ZIM LABORATORIES Gains 10%; BSE HEALTHCARE Index Up 0.7%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!